Antinociceptive effect of N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide on different pain models in mice

N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide (DDIAHB) is a new drug developed through molecular modelling and rational design by the association of epinastine salicylic acid. The present study was designed to assess possible antinociceptive effects DDIAHB on different pain models in male ICR mice. exerted reductions writhing numbers behavior observed during second phase formalin test dose-dependent manner. Moreover, increased latency hot-plate Furthermore, intragastric administration caused reversals decreased threshold both streptozotocin-induced diabetic neuropathy vincristine-induced peripheral models. Additionally, pretreatment with also reversal monosodium urate-induced model. We characterized signaling mechanism effect-induced spinal iNOS, p-STAT3, p-ERK p-P38 levels induced injection. Our results suggest that shows an property various effect appear be mediated expression cord formalin-induced